BR112016024841A2 - composições estáveis de peptídeos neuroativos - Google Patents

composições estáveis de peptídeos neuroativos

Info

Publication number
BR112016024841A2
BR112016024841A2 BR112016024841A BR112016024841A BR112016024841A2 BR 112016024841 A2 BR112016024841 A2 BR 112016024841A2 BR 112016024841 A BR112016024841 A BR 112016024841A BR 112016024841 A BR112016024841 A BR 112016024841A BR 112016024841 A2 BR112016024841 A2 BR 112016024841A2
Authority
BR
Brazil
Prior art keywords
stable
peptide compositions
neuroactive peptide
neuroactive
compositions
Prior art date
Application number
BR112016024841A
Other languages
English (en)
Inventor
Renwick Houck David
Arghavani Mohsen
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of BR112016024841A2 publication Critical patent/BR112016024841A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

a divulgação refere-se a formulações intravenosas de peptídeos glyx para o tratamento de transtornos do cns tais como depressão, dor neuropática ou ansiedade.
BR112016024841A 2014-04-25 2015-04-27 composições estáveis de peptídeos neuroativos BR112016024841A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461984216P 2014-04-25 2014-04-25
PCT/US2015/027745 WO2015164859A1 (en) 2014-04-25 2015-04-27 Stable compositions of neuroactive peptides

Publications (1)

Publication Number Publication Date
BR112016024841A2 true BR112016024841A2 (pt) 2017-10-24

Family

ID=54333349

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016024841A BR112016024841A2 (pt) 2014-04-25 2015-04-27 composições estáveis de peptídeos neuroativos

Country Status (14)

Country Link
US (2) US20170049844A1 (pt)
EP (2) EP3134103B1 (pt)
JP (1) JP6702883B2 (pt)
KR (1) KR20160144499A (pt)
CN (2) CN112716890A (pt)
AU (2) AU2015249222A1 (pt)
BR (1) BR112016024841A2 (pt)
CA (1) CA2946413A1 (pt)
CL (1) CL2016002704A1 (pt)
IL (1) IL248433B (pt)
RU (1) RU2716164C2 (pt)
SG (2) SG11201608896QA (pt)
UA (1) UA122204C2 (pt)
WO (1) WO2015164859A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019113102A1 (en) 2017-12-05 2019-06-13 Naurex Inc. Nmda receptor modulators (rapastinel) combination for use in combined treatment (sleep and cns disorder)
US20220024976A1 (en) * 2019-01-11 2022-01-27 Naurex Inc. Salt and crystalline forms of rapastinel

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
NZ212207A (en) * 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
HN1998000106A (es) * 1997-08-01 1999-01-08 Pfizer Prod Inc Composiciones parenterales de alatroflaxacino
JP2008519007A (ja) * 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
CN102772358A (zh) * 2005-06-16 2012-11-14 美瑞德生物工程公司 药物组合物及其用途
KR20090024248A (ko) * 2006-06-12 2009-03-06 쉐링 코포레이션 Ｃｘｃｒ2의 선택적 길항제 또는 ｃｘｃｒ1과 ｃｘｃｒ2 둘다의 선택적 길항제의 약제학적 제형 및 조성물, 및 염증성 질환을 치료하기 위한 이의 사용방법
US20120178695A1 (en) * 2009-07-02 2012-07-12 Joseph Moskal Methods of treating neuropathic pain
US9101612B2 (en) * 2010-02-11 2015-08-11 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
JP2014522827A (ja) * 2011-06-28 2014-09-08 ロイコケア・アクチェンゲゼルシャフト （ポリ）ペプチドのアンフォールディングを防止し、および／または（ポリ）ペプチドの（リ）フォールディングを誘導するための方法
EP2572736A1 (en) * 2011-09-23 2013-03-27 Spago Imaging AB Nanostructures comprising manganese
WO2013188465A2 (en) * 2012-06-13 2013-12-19 Arizona Board Of Regents, For And On Behalf Of, Arizona State University Pharmaceutical compositions and methods for treating drug addiction and preventing a drug relapse
US20140050789A1 (en) * 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids

Also Published As

Publication number Publication date
RU2016144342A (ru) 2018-05-28
KR20160144499A (ko) 2016-12-16
AU2015249222A1 (en) 2016-11-17
US20200254050A1 (en) 2020-08-13
EP3689362A1 (en) 2020-08-05
JP2017514817A (ja) 2017-06-08
RU2016144342A3 (pt) 2018-11-13
SG10201803880TA (en) 2018-07-30
EP3134103B1 (en) 2020-01-15
RU2716164C2 (ru) 2020-03-06
EP3134103A4 (en) 2017-12-27
WO2015164859A1 (en) 2015-10-29
EP3134103A1 (en) 2017-03-01
CN112716890A (zh) 2021-04-30
IL248433B (en) 2020-03-31
IL248433A0 (en) 2016-12-29
JP6702883B2 (ja) 2020-06-03
SG11201608896QA (en) 2016-11-29
UA122204C2 (uk) 2020-10-12
CL2016002704A1 (es) 2017-06-30
CN106535913B (zh) 2021-01-26
CN106535913A (zh) 2017-03-22
AU2020277278A1 (en) 2021-01-07
CA2946413A1 (en) 2015-10-29
US20170049844A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
BR112016025048A2 (pt) compostos e composições como agonistas do receptor tipo toll7
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
BR112017010173A2 (pt) composição para tratamento de tecido
EA201790273A1 (ru) Флагеллиновые композиции и их применение
PH12019501359A1 (en) Polymorphs
MX2016013447A (es) Heterociclilsulfonas heteroarilo sustituidas.
CL2017001310A1 (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
BR112017009289A2 (pt) métodos de administrar composições de amantadina
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
PH12016501613A1 (en) Pyrazines modulators of gpr6
TN2016000177A1 (en) P-substituted asymmetric ureas and medical uses thereof
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
BR112016024841A2 (pt) composições estáveis de peptídeos neuroativos
MX2016013451A (es) Heterociclilsulfonas arilo sustituidas.
JO3621B1 (ar) مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2772 DE 20/02/2024.